Screener
ArriVent BioPharma, Inc. AVBP Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:08 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-058650
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $62,103 | $45,540 |
| Short-term investments | 264,277 | 267,281 |
| Prepaid expenses and other current assets | 22,320 | 20,076 |
| Total current assets | 348,700 | 332,897 |
| Right of use assets – operating leases | 370 | 13 |
| Deferred offering costs | 69 | 69 |
| Other assets | 156 | 190 |
| Total assets | $349,295 | $333,169 |
Item 1. Condensed Financial Statements (Unaudited):
FAQ
- What is ArriVent BioPharma, Inc.'s total current assets?
- ArriVent BioPharma, Inc. (AVBP) reported total current assets of $348.7M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total current assets changed year-over-year?
- ArriVent BioPharma, Inc.'s total current assets increased by 87.7% year-over-year, from $185.79M to $348.7M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total current assets?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total current assets has grown at a 44.3% compound annual growth rate (CAGR), from $159.97M to $332.9M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about ArriVent BioPharma, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude